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Abstract
Background:  Lipids, particularly low-density (LDL) and high-density (HDL) lipoproteins, are
associated with increased risk of stroke and cardiovascular disease, probably due to
atherosclerosis. The objective of this cross-sectional analysis was to investigate the relation
between blood lipids and carotid plaque.
Methods: As part of a prospective population-based study to determine the incidence and risk
factors of stroke in a multiethnic population, we evaluated 1804 participants with lipid
measurements and B-mode ultrasound of carotid arteries (mean age 69 +/- 10 years; 40% men; 51%
Hispanic, 26% black, 23% white). The association between lipid parameters and carotid plaque was
analyzed by multiple logistic regression.
Results: Plaque was present in 61% of participants. Mean total cholesterol was 202 +/- 41 mg/dl.
After controlling for other lipid parameters, demographics, and risk factors, the only cholesterol
subfraction associated with carotid plaque was LDL (OR per standard deviation (SD) = 1.14, 95%
CI 1.02-1.27). Neither HDL nor triglycerides independently predicted carotid plaque.
Apolipoprotein B (ApoB) was also associated with risk of plaque (OR per SD = 1.29, 95% CI 1.03-
1.60). Apolipoprotein A-I (apoA-1) was associated with a decrease in multiple plaques (OR per SD
= 0.76, 95% CI 0.60-0.97), while lipoprotein a was associated with an increased risk of multiple
plaques (OR per SD = 1.31, 95% CI 1.03-1.66). ApoB:ApoA-I had the strongest relation with
carotid plaque (OR per SD = 1.35, 95% CI 1.08-1.69).
Conclusions: Among the common lipid parameters, LDL has the strongest relation with carotid
plaque. Other lipid precursor proteins such as ApoB and ApoA-I may be stronger predictors of
subclinical atherosclerosis, however, and better targets for treatment to reduce plaque formation
and risk of cerebrovascular disease.
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Background
Blood lipids levels, particularly elevated low-density lipo-
protein (LDL) and decreased high-density lipoprotein
(HDL), have been definitely associated with an increased
risk of cardiovascular disease (CVD) and less clearly asso-
ciated with stroke [1-4]. While there are several possible
mechanisms underlying the association of lipids and
stroke [5-7], one of the most important is probably the
effects of lipids on the formation of carotid artery athero-
sclerotic plaque [8].
Although the protective effect of lipid-lowering medica-
tion on CVD and stroke risk is well-established [4,9,10],
data regarding the relative importance of the various lipid
parameters, total cholesterol (T-CHOL), LDL, HDL, non-
HDL cholesterol, triglycerides (TG), lipoprotein a (Lp(a)),
apolipoprotein (Apo) B and A-I, to CVD and stroke risk is
inconclusive. A large prospective cohort study of women
indicated a significantly elevated risk of first cardiovascu-
lar events, including ischemic stroke, among those at the
extreme quintiles of all lipid parameters, including ApoA-
I and ApoB, the major protein constituents of HDL and
LDL, respectively. The most predictive parameters were
non-HDL, HDL, and ApoB, and the lipid ratios were even
more predictive, particularly T-CHOL:HDL [1]. Informa-
tion regarding the association between lipid parameters
and plaque formation is also limited, particularly in
racially diverse populations.
While it has been suggested that ApoB and ApoA-I may
play a more influential role in CVD prevention than total
LDL and HDL, further research is needed to understand
the optimal indicators of effective lipid-lowering treat-
ment in patients at risk for stroke. The goal of this popu-
lation-based study is to elucidate the relation between
lipid levels and carotid plaque presence in a multi-ethnic
cohort. Due to the complexity of lipid effects on athero-
sclerosis we hypothesize that the ratio of lipid parameters,
rather than single lipid parameters, will be most associ-
ated with carotid plaque phenotypes. The association
between lipid parameters, including lipid ratios, and vari-
ous cardiovascular outcomes has been well-studied. How-
ever, research among Hispanic populations is lacking and
is particularly important due to the growing population of
Hispanics in the United States and the perception of evi-
dence for a Hispanic paradox, which suggests that Hispan-
ics have better cardiovascular health than what would be
predicted based on their vascular risk factor profile.
Methods
Subjects
The Northern Manhattan Study (NOMAS) is a prospec-
tive, population-based, cohort study documenting stroke
incidence, risk factors, and prognosis in a multiethnic
urban community. Based in northern Manhattan, an area
of approximately 260,000 people with 104,000 over age
39 in 1990, this study population has a unique race/eth-
nic distribution that is over 50% Hispanic. Methodology
for NOMAS has been described previously [11].
A total of 3298 subjects were recruited and enrolled from
1993-2001. Eligible participants (1) had never been diag-
nosed with an ischemic stroke, (2) were ≥40 years old,
and (3) resided for at least three months in a household
with a telephone in northern Manhattan. Subjects were
identified by random-digit dialing, and interviews were
conducted by trained bilingual interviewers [12]. This
study was approved by the University of Miami institu-
tional review board, and written consent was obtained.
Subjects were recruited from the telephone sample to have
an in-person baseline interview and assessment. The
enrollment response rate was 75%. Standardized ques-
tions were adapted from the validated Centers for Disease
Control and Prevention Behavioral Risk Factor Surveil-
lance System [13,14].
Exposure Assessment
Blood samples were drawn after an overnight fast. Plasma
levels of cholesterol and triglycerides were measured using
standardized enzymatic procedures with a Hitachi 705
automated spectrophotometer (Boehringer Mannheim,
Mannheim, Germany). HDL was measured after precipi-
tation of plasma apo B-containing lipoproteins with
phosphotungstic acid. LDL was calculated using the
Friedewald et al. equation [15]. The inter-assay coeffi-
cients of variation in our laboratory were 2% for T-CHOL,
4% for triglycerides, and 3% for HDL [16]. In addition to
T-CHOL and its subfractions, serum levels of the LDL and
HDL constituents, ApoB and ApoA-I, were also collected
by commercially available immunonephelometric proce-
dures. The interassay coefficients of variation for these
measurements were 3-5% [17]. Lp(a) levels were deter-
mined using a rate nephelometric assay (Beckman Instru-
ments, Brea, CA) adapted for use on a Beckman Array 360
nephelometer, as described previously [17,18]. Lp(a)
antibody was obtained from Dako Chemicals (Carpinte-
ria, CA), and Lp(a) standards were purchased from Inter-
national Enzymes (Fallbrook, CA). These standards have
been standardized against the Northwest Research Lipid
Laboratories (Seattle, WA). This assay had coefficients of
variation of 4% and 8% at Lp(a) levels of 48 and 8 mg/dl,
respectively.
Outcome Assessment
Carotid artery plaque presence was assessed by high-reso-
lution B-mode ultrasound using a GE LogIQ 700 system
with a multifrequency 9 to 13 MHz linear-array trans-
ducer. Carotid ultrasounds were performed according to
standard scanning and reading protocols by trained andBMC Cardiovascular Disorders 2009, 9:55 http://www.biomedcentral.com/1471-2261/9/55
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certified technologists as detailed previously [19-21]. Left
and right carotid bifurcations and internal and common
carotid arteries were examined for plaque presence.
Plaque was defined as an area of focal wall thickening
50% greater than surrounding wall thickness confirmed
by marking and comparing plaque thickness with that of
the surrounding wall during scanning by electronic cali-
pers. The plaque boundaries were traced manually from
the digitized multiangled images. Maximum carotid
plaque thickness (MCPT, millimeters) was measured at
the peak plaque prominence from any of the three carotid
artery segments using a semi-automatic IMAGE-Pro V.5.2
software (Microsoft). The intraclass correlation coeffi-
cients for within and between reader variability of plaque
thickness measurements were 0.94 and 0.77, respectively
(n = 88) [22]. Plaque surface characteristics (regular, irreg-
ular) were also recorded, and intra- and interrater correla-
tions of plaque surface characteristics were greater than
0.90 in our laboratory.
The primary outcome of interest was any plaque presence,
and secondary outcomes were (1) MCPT >1.9 mm, (2)
more than one plaque in the carotid arteries, and (3) irreg-
ular plaque. Each of these outcomes was compared to the
lack of plaque as the reference. A MCPT cutoff of 1.9 mm
was used because it was previously shown to be predictive
of cardiovascular events in this study population [23].
Covariates
Covariates in multivariate analyses included demographic
and vascular risk factors measured at baseline. Hyperten-
sion was defined as a self-reported history of hypertension
or a measured systolic blood pressure ≥140 or diastolic
blood pressure ≥90 mmHg. Diabetes was defined as self-
report of such history or a fasting blood sugar ≥126 mg/
dL. Body mass index (BMI) was measured continuously as
kg/m2. Pipe and cigar smoking was assessed by self-report
and categorized as current (within one year), former, and
never smoker. Cigarette smoking was also assessed by self-
report and defined in pack-years. Moderate alcohol use
was defined as current drinking of >1 drink per month
and ≤2 drinks per day. Leisure-time/recreation physical
activity was assessed by a questionnaire [24]. Moderate to
heavy physical activity level was defined as engaging in
one or more of selected rigorous physical activities in a
typical 14-day period. Race and ethnicity were defined by
self-identification based on a series of interview questions
modeled after the US census and was categorized as His-
panic, non-Hispanic white, and non-Hispanic black. Indi-
viduals of other race/ethnicity were excluded.
Statistical Analyses
The following lipid levels were assessed continuously, as
the primary exposures of interest: T-CHOL, HDL, LDL,
TG, non-HDL (T-CHOL-HDL), ApoB, ApoA-I, and Lp(a).
The following lipid ratios were also calculated and
assessed continuously: T-CHOL:HDL, LDL:HDL, and
ApoB:ApoA-I. Independent samples t-tests were con-
ducted as univariate analyses to compare the lipid param-
eters among those with each of the plaque outcome
criteria vs. those with no carotid plaque.
Multiple logistic regression analyses were conducted to
examine the association between lipid parameters and
plaque outcomes, controlling for other pertinent lipid
parameters, demographics (age, sex, race/ethnicity), vas-
cular and lifestyle risk factors (hypertension, diabetes,
BMI, pipe or cigar smoking, pack-years of cigarette smok-
ing, moderate alcohol use, moderate-to-heavy physical
activity), and the change in time between lipid and plaque
measurements.
Analyses of LDL, HDL, and triglycerides were mutually
adjusted for each other; Non-HDL was adjusted for HDL;
Lp(a) and ApoB were adjusted for HDL and triglycerides;
ApoA-I was adjusted for LDL and triglycerides. For all lipid
parameters the odds ratios (OR) and 95% confidence
intervals (CI) are reported for a 1 standard deviation (SD)
increase.
We explored potential heterogeneity by race/ethnicity,
sex, and age in the association between total cholesterol
and its subfractions with presence of plaque by adding
interaction terms in the multivariate analyses.
The total number of individuals with measurements of
both carotid plaque and T-CHOL and its subfractions
(LDL, HDL, triglycerides) was 2341, from which 537 were
excluded because their carotid ultrasounds were con-
ducted more than a year prior to their blood lipid meas-
urements. Therefore, the total sample size for this study
was 1804, of which 568 had measurement of ApoB and
ApoA-I and 582 had Lp(a). Only 3% of the study popula-
tion had missing covariate data.
Results
Plaque was present in 61% of participants (N = 1106), of
whom 211 (19%) had irregular plaque, 727 (66%) had
multiple plaques, and 514 (46%) had MCPT >1.9 mm.
Plaque was observed most commonly in the internal
carotid artery and bifurcation (N = 1093, 99% of those
with plaque), and less frequently in the common carotid
artery (N = 123, 11% of those with plaque).
Table 1 shows the characteristics of the study population,
overall and stratified by plaque presence. Twenty-two per-
cent had LDL <100, 33% had LDL 100-130, 27% 130-
160, and 17% >160 mg/dl. Thirty-one percent had HDL
levels <40, 32% had HDL between 40-50, and 36% >50
mg/dl. Only 13% of the study population reported takingBMC Cardiovascular Disorders 2009, 9:55 http://www.biomedcentral.com/1471-2261/9/55
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lipid-lowering medication, as the baseline data were col-
lected prior to the publication of the ATP III guidelines.
Tables 1 and 2 show the mean ± SD for each of the lipid
parameters, stratified by plaque outcome criteria. Individ-
uals with each plaque outcome had higher ApoB and
ApoB:ApoA-I ratio than those with no plaque, and those
with multiple plaques also had slightly elevated LDL.
Table 3 shows the OR and 95% CI for the relation
between each of the lipid parameters and each of the
carotid plaque outcomes in the multivariate-adjusted
models. Increased T-CHOL, LDL, non-HDL, ApoB, T-
CHOL:HDL, LDL:HDL, and ApoB:ApoA-I were associated
with plaque presence, whereas HDL, triglycerides, Lp(a),
and ApoA-I were not. A 1-SD increase in T-CHOL (mg/dL)
was associated with a 12% increased risk of plaque. Of the
total cholesterol subfractions, only LDL was an independ-
Table 1: Characteristics of the study population: overall and by plaque presence
Overall (N = 1804) No plaque (N = 698) Plaque (N = 1106)
Covariates
Age (Mean ± SD) 68.5 ± 10.1 64.5 ± 9.6 71.1 ± 9.5a
Male sex (%) 39.8 37.8 41.0
Race/ethnicity
Hispanic (%) 51.4 61.6 44.9a
Black (%) 25.5 22.1 27.7a
White (%) 23.1 16.3 27.4a
Hypertension (%) 73.5 68.6 76.5a
Diabetes (%) 21.2 18.8 22.7a
Cigarette smoker
Current (%) 15.5 12.2 17.6 a
Former (%) 37.8 32.7 40.9 a
Pipe or cigar smoker
Current (%) 2.3 1.5 2.7a
Former (%) 5.9 4.4 6.8 a
Moderate alcohol consumption (%) 35.1 34.7 35.3
Moderate to heavy physical activity (%) 10.0 12.0 8.8a
BMI (Mean ± SD) 27.9 ± 5.6 28.3 ± 5.6 27.7 ± 5.6a
Lipid Parameters (Mean ± SD)
Total cholesterol (N = 1804) 202 ± 41 200 ± 40 203 ± 42
LDL (N = 1804) 127 ± 37 125 ± 37 128 ± 37
HDL (N = 1804) 48 ± 15 48 ± 15 48 ± 15
Triglycerides (N = 1804) 133 ± 71 135 ± 80 133 ± 65
Non-HDL (N = 1804) 154 ± 41 152 ± 40 155 ± 42
Lp(a) (N = 582) 41 ± 41 39 ± 36 43 ± 44
ApoB (N = 568) 113 ± 30 108 ± 29 116 ± 30a
ApoA-I (N = 568) 146 ± 28 147 ± 29 145 ± 27
T-CHOL:HDL (N = 1804) 4.58 ± 1.57 4.54 ± 1.52 4.60 ± 1.61
LDL:HDL (N = 1804) 2.92 ± 1.24 2.87 ± 1.18 2.95 ± 1.27
ApoB:ApoA-I (N = 568) 0.81 ± 0.29 0.77 ± 0.30 0.83 ± 0.28a
a p < 0.05 vs. no plaque, X2 test for categorical variables and t-test for continuous variables
Table 2: Mean and SD of lipid parameters, stratified by carotid plaque outcomes
Mean ± SD Multiple plaques (N = 727) Thickness >1.9 mm (N = 514) Irregular plaque (N = 211)
Total cholesterol 203 ± 43 204 ± 41 203 ± 45
LDL 129 ± 38a 129 ± 36 129 ± 41
HDL 47 ± 15 48 ± 16 48 ± 15
Triglycerides 135 ± 67 131 ± 60 131 ± 65
Non-HDL 156 ± 43 155 ± 40 155 ± 47
Lp(a) 45 ± 45 44 ± 43 40 ± 33
ApoB 118 ± 29a 117 ± 31a 125 ± 36a
ApoA-I 144 ± 28 145 ± 28 143 ± 28
T-CHOL:HDL 4.68 ± 1.65 4.59 ± 1.60 4.57 ± 1.81
LDL:HDL 3.01 ± 1.30 2.95 ± 1.27 2.93 ± 1.45
ApoB:ApoA-I 0.85 ± 0.29a 0.84 ± 0.30a 0.91 ± 0.35a
ap < 0.05 vs. no plaque (t-test)BMC Cardiovascular Disorders 2009, 9:55 http://www.biomedcentral.com/1471-2261/9/55
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ent predictor of plaque (OR for a 1-SD increase = 1.14). As
triglycerides were not associated with plaque, LDL is driv-
ing the association with non-HDL (OR for a 1-SD increase
in non-HDL = 1.13). The LDL precursor protein ApoB was
even more predictive of plaque presence than LDL (OR for
a 1-SD increase = 1.29).
Although the ratios T-CHOL:HDL and LDL:HDL were
positively associated with plaque, as well as the presence
of multiple plaques and thick plaque, in the multivariate
analyses, the ratio of precursor proteins ApoB:ApoA-I was
far more predictive, with a 35% increased risk of plaque
observed for a 1-SD increase in ApoB:ApoA-I.
When the models were further adjusted for lipid-lowering
medication use, the conclusions remained unchanged
(data not shown). Interaction terms were added to the
multivariate models to examine potential effect modifica-
tion by race/ethnicity, sex, and age, and no significant
interactions were observed.
The relative risk estimates for T-CHOL, LDL, non-HDL,
and LDL:HDL were attenuated when the outcome was
restricted to irregular plaque (vs. no plaque), although the
association with ApoB appeared stronger. In contrast, the
lipid parameters were generally more strongly predictive
when the outcome was restricted to the presence of multi-
ple plaques. Individuals with multiple plaques had signif-
icantly elevated levels of Lp(a) and lower ApoA-I.
Discussion
The results indicate a strong relation between blood lipid
levels and presence of carotid plaque in our multi-ethnic
population, suggesting that blood lipids likely influence
the risk of cardiovascular diseases and particularly stroke
due to their effects on atherosclerotic plaque formation.
Elevated LDL was independently associated with carotid
plaque. However, HDL and triglycerides were not signifi-
cantly associated with plaque presence after controlling
for other lipid parameters and vascular risk factors. An
analysis of precursor proteins supported the strength of
the LDL association, as ApoB, the LDL precursor protein,
was associated with an increased risk of plaque, whereas
ApoA-I, the HDL precursor protein, was not. In fact, the
lipid parameter most predictive of plaque presence was
ApoB, and particularly the ratio ApoB:ApoA-I.
Despite the lower prevalence of carotid plaque observed
among the Hispanic participants, the effect of lipid levels
on plaque risk was not different among the Hispanics in
comparison to the other race/ethnic groups. Therefore, we
did not find evidence in support of the Hispanic paradox
[25] regarding the effect of blood lipids. Further research
is needed on vascular risk factors for subclinical athero-
sclerosis in Hispanics, as Hispanics comprise the fastest
growing minority population in the United States, and it
is important for clinicians to be aware of possible race/
ethnic differences in the etiology of vascular disease.
Although current clinical practices involve the measure-
ment of T-CHOL, LDL, HDL, and triglycerides to inform
treatment decisions, the results of the current study sug-
gest that the precursor protein ApoB and, to a lesser
extent, ApoA-I may be stronger predictors of subclinical
atherosclerosis, and therefore may be helpful parameters
to use in clinical practice. In fact, the ratio ApoB:ApoA-I
may be the best predictor of risk of atherosclerosis and
likewise the optimal measure to assess new lipid-lowering
medication, as treatment regimens that lower ApoB are
likely to be most effective in reducing plaque formation.
Table 3: Association between lipid parameters and carotid plaque outcomes, adjusted for demographics and vascular risk factorsa
OR (95% CI)b vs. No plaque
Plaque Multiple plaques Thickness >1.9 mm Irregular plaque
Total cholesterol 1.12 (1.01-1.25) 1.15 (1.02-1.30) 1.11 (0.97-1.27) 1.08 (0.91-1.28)
LDL 1.14 (1.02-1.27) 1.16 (1.03-1.31) 1.13 (0.99-1.29) 1.09 (0.91-1.29)
HDL 0.97 (0.86-1.09) 0.91 (0.79-1.05) 0.96 (0.83-1.11) 1.10 (0.90-1.33)
Triglycerides 0.99 (0.88-1.10) 1.04 (0.92-1.18) 1.01 (0.88-1.16) 0.97 (0.81-1.17)
Non-HDL 1.13 (1.01-1.26) 1.17 (1.03-1.33) 1.12 (0.98-1.28) 1.07 (0.90-1.28)
Lp(a) 1.21 (0.99-1.48) 1.31 (1.03-1.66) 1.22 (0.94-1.58) 1.05 (0.55-1.99)
ApoB 1.29 (1.03-1.60) 1.29 (1.00-1.66) 1.35 (1.04-1.75) 1.56 (0.95-2.56)
ApoA-I 0.85 (0.70-1.05) 0.76 (0.60-0.97) 0.80 (0.63-1.03) 0.83 (0.48-1.41)
T-CHOL:HDL 1.13 (1.01-1.26) 1.23 (1.08-1.40) 1.16 (1.01-1.33) 1.00 (0.83-1.19)
LDL:HDL 1.16 (1.04-1.29) 1.25 (1.10-1.41) 1.18 (1.03-1.36) 1.03 (0.86-1.23)
ApoB:ApoA-I 1.35 (1.08-1.69) 1.49 (1.15-1.94) 1.41 (1.08-1.84) 1.46 (1.06-2.01)
a age, sex, race/ethnicity, hypertension, diabetes, BMI, pack-years of cigarette smoking, pipe or cigar smoking (past/current/never), moderate alcohol 
use, moderate to heavy physical activity, and the change in time between lipid and plaque measurements
b 1 SD increaseBMC Cardiovascular Disorders 2009, 9:55 http://www.biomedcentral.com/1471-2261/9/55
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The atherosclerotic process is very complex and involves
several different mechanisms including injury in the
endothelium, activation of immuno-inflammatory cells,
smooth muscle cell proliferation, and influx of lipopro-
teins through the vessel injury space [26,27]. The results
of the current study do not suggest that HDL is unrelated
to carotid plaque presence. Rather, they indicate that it is
the relative levels of LDL and HDL that may be more pre-
dictive than either LDL or HDL alone, and that the HDL
precursor protein ApoA-I may be more etiologically rele-
vant than the overall HDL level. The anti-atherogenic
property of HDL has been documented in both clinical
observations and laboratory settings [28], as HDL has
been shown to have both direct and indirect anti-inflam-
matory effects with potential antithrombotic results [29].
The main beneficial role of HDL is its capacity to reverse
cholesterol transport, removing free cholesterol from the
macrophage in the endothelium and returning it to the
liver for excretion into bile, thereby protecting against
atherosclerotic plaque formation [5].
The association between the ApoB:ApoA-I ratio and devel-
opment of atherosclerosis [30,31] and cardiovascular dis-
ease [32] has been shown. ApoB assembles the precursor
of very-low-density lipoprotein, a component of LDL,
while ApoA-I is necessary for the metabolism of HDL.
Modification of the ApoB:ApoA-I ratio may affect athero-
sclerotic plaque development [33]. Interestingly, it has
been shown that, unlike lipoproteins LDL and HDL, the
apolipoproteins remain stable with age and cardiovascu-
lar disease severity [34]. We did not show that Lp(a) was
independently associated with carotid plaque presence,
although it was predictive of the presence of multiple
plaques, and therefore may be associated with a greater
plaque burden. The restricted sample of NOMAS individ-
uals with Lp(a) measured limited the statistical power of
these analyses. Data on the etiologic importance of Lp(a)
has been controversial, as Lp(a) has been more related to
the mechanisms of thrombosis and fibrinolysis. A recent
study showed that Lp(a) was independently associated
with carotid stenosis and occlusion, but not with plaque
area [35]. A substudy of 426 individuals selected from the
NOMAS population previously showed that maximum
internal carotid artery plaque thickness was not associated
with Lp(a) levels, but it was associated with the amount of
Lp(a) carrying the small apo(a) size [36].
We did not find that triglycerides were associated with
plaque presence after controlling for other lipid parame-
ters and vascular risk factors. It has been shown that trig-
lycerides are the lipid subfraction least present inside
atherosclerotic plaque [37]. Furthermore, the fact that
triglyceride levels vary considerably within individuals
makes it more difficult to evaluate them as a risk factor for
atherosclerosis. Other studies have also demonstrated no
significant association between triglycerides and carotid
plaque after controlling for other lipid parameters and
vascular risk factors [38,39].
Carotid plaque, particularly thick plaque and irregular
plaque, has been shown to be a risk factor for vascular
events, including stroke [23,40-42]. Because lipids likely
influence the risk of CVD and stroke due to their effects on
atherosclerotic plaque formation, carotid plaque may be
used as a surrogate endpoint in epidemiologic and phar-
macologic studies of lipid treatment.
The various lipid parameters and lipid ratios examined in
our study have been shown to be predictive of combined
cardiovascular events in a large population-based study of
women in which the lipid parameters were not mutually
adjusted for each other [1]. Interestingly, the strongest
effect estimate was observed for non-HDL. This study
showed that the lipid ratios were more predictive of cardi-
ovascular disease risk than any of the individual lipid lev-
els. However, unlike our study, the weakest association
was observed for the ratio of ApoB:ApoA-I. Although lipid
parameters have been well-established as predictors of
coronary heart disease, their role in the pathogenesis of
stroke has been more controversial. In the Atherosclerotic
Risk in Communities (ARIC) study, investigators reported
weak and inconsistent [nonlinear] associations between
LDL, HDL, triglycerides, ApoB, and ApoA-I with ischemic
stroke risk [43]. In contrast, two other large studies have
demonstrated strong associations between T-CHOL and
its subfractions with risk of ischemic stroke [44,45]. Lipid
parameters have also been shown to be related to carotid
intima-media thickness (IMT), a related yet distinct meas-
ure of subclinical atherosclerosis [34].
Studies examining the effects of lipid-lowering treatments
have provided strong evidence for an important role of
lipids, particularly LDL, in stroke risk. Two meta-analyses
have suggested an 18% decreased risk of stroke among sta-
tin users as compared to controls [46,47]. The SPARCL
study demonstrated a decreased risk of recurrent stroke in
individuals treated with atorvastatin following a previous
stroke or TIA [48]. A recent meta-analysis also suggested
that the effect of statins on both stroke risk and carotid
IMT progression observed across studies was closely asso-
ciated with the reduction in LDL cholesterol [49].
Strengths of the current study include its large and ethni-
cally-diverse sample population, including Hispanics, col-
lection of information on correlated vascular risk factors
necessary to estimate the independent association
between lipids and carotid plaque, assessment of a range
of lipid parameters, including Lp(a) which has been rela-
tively unstudied, and the measurement of various plaque
characteristics in addition to its simple presence (e.g.BMC Cardiovascular Disorders 2009, 9:55 http://www.biomedcentral.com/1471-2261/9/55
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thickness, irregularity, number). However, a primary lim-
itation is the cross-sectional nature of this study. Further
research in other populations is necessary to examine the
association between lipid levels ascertained longitudi-
nally and the progression of carotid plaque, in order to
better understand the temporality of the relation. In addi-
tion, information on Lp(a), ApoB, and ApoA-I were avail-
able for a subsample, limiting the statistical power with
which to examine these less traditional lipid parameters.
Conclusions
In conclusion, our study supports the role of total choles-
terol, LDL, and particularly the precursor protein ApoB as
predictors of carotid atherosclerotic plaque in a multi-eth-
nic population, independent of other traditional vascular
risk factors. Results suggest that ApoB may be the best tar-
get for treatment in people at risk for atherosclerosis and
cerebrovascular disease. The current study provides novel
information on the relative utility of various lipid param-
eters in predicting carotid plaque, an important subclini-
cal marker of atherosclerosis, and contributes to the
growing evidence for the superior prognostic value of the
apolipoproteins.
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